MORAb-003 is a humanized IgG1 antibody that targets Folate Receptor Alpha which is over-expressed on a number of epithelial-derived cancers such as ovarian, breast, renal, lung, colorectal and brain cancers. MORAb-003 received orphan drug designation by the FDA for ovarian cancer.

MORAb-003 is currently being developed as a therapeutic antibody for the treatment of ovarian cancer. Investigational New Drug (IND) application was opened for MORAb-003 in 2005. A Phase I study conducted at Memorial Sloan Kettering Cancer Center (2007 ASCO Poster) showed the antibody to be well tolerated. A multi-institutional Phase II Study is currently being conducted in platinum-sensitive ovarian cancer patients in North America and Europe (2007 ASCO Abstract). For more information about this ongoing clinical trialsclick here.